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AbstrAct
A key focus in cancer immunotherapy is to investigate the mechanism of 
efficacious vaccine responses. Using HIV-1 GAG-p24 in a model PD1-based 
DNA vaccine, we recently reported that vaccine-elicited CD8+ T cells conferred 
complete prevention and therapeutic cure of AB1-GAG malignant mesothelioma 
in immunocompetent BALB/c mice. Here, we further investigated the efficacy and 
correlation of protection on the model vaccine-mediated antigen spreading against 
wild-type AB1 (WT-AB1) mesothelioma. We found that this vaccine was able to protect 
mice completely from three consecutive lethal challenges of AB1-GAG mesothelioma. 
Through antigen spreading these animals also developed tumor-specific cytotoxic 
CD8+ T cells, but neither CD4+ T cells nor antibodies, rejecting WT-AB1 mesothelioma. 
A majority of these protected mice (90%) were also completely protected against the 
lethal WT-AB1 challenge. Adoptive cell transfer experiments further demonstrated 
that antigen spreading-induced CD8+ T cells conferred efficacious therapeutic effects 
against established WT-AB1 mesothelioma and prevented the increase of exhausted 
PD-1+ and Tim-3+ CD8+ T cells. A significant inverse correlation was found between 
the frequency of functional PD1-Tim3- CD8+ T cells and that of MDSCs or tumor mass 
in vivo. Mechanistically, we found that WT-AB1 mesothelioma induced predominantly 
polymorphonuclear (PMN) MDSCs in vivo. In co-cultures with efficacious CD8+ T cells, 
a significant number of PMN-MDSCs underwent apoptosis in a dose-dependent way. 
Our findings indicate that efficacious CD8+ T cells capable of eliminating both tumor 
cells and MDSCs are likely necessary for fighting wild-type malignant mesothelioma.
INtrODUctION
Immune surveillance is considered to be an 
important host defense mechanism to maintain cellular 
homeostasis and to inhibit carcinogenesis [1]. Effector 
CD8+ T cell or cytotoxic T lymphocyte (CTL) plays a 
key role in immune surveillance by eliminating antigen-
specific target cells during tumor immunotherapy [2]. 
The universality of MHC class I molecule expression 
allows CTLs to selectively recognize peptides from 
diverse tumor antigens [3]. After the recognition of 
peptide-MHC complex, CTLs can lyse target tumor 
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cells with the involvement of perforin and/or granzymes, 
and by releasing cytokines (e.g., IFN-γ) and initiating 
death receptor-mediated apoptosis pathways [4, 5]. 
Therefore, the induction of high frequency of long-lasting 
effector CD8+ T cells has been a key focus in cancer 
immunotherapy research. 
We previously reported that a PD1-based DNA 
vaccine, namely sPD1-p24fc, when delivered via in 
vivo electroporation (EP), induces a high frequency of 
antigen-specific CD8+ T cells with broad reactivity, long-
term memory, polyfunctionality and cytotoxicity [6]. 
Furthermore, using this model sPD1-p24fc/EP vaccine, we 
recently demonstrated that vaccine-elicited CD8+ T cells 
conferred complete prevention and therapeutic cure of 
AB1-GAG malignant mesothelioma [5]. The efficacy was 
attributed to vaccine-elicited CD8+ T cells that could retain 
their effector functions once infiltrated into the tumor [7], 
reduce myeloid-derived suppressor cells (MDSCs) and 
CD4+CD25+Foxp3+ regulatory T lymphocytes (Treg) cell 
populations [8, 9], and lead to the complete clearance of 
tumor cells [5, 7]. Thus, if the vaccine is highly potent, it 
is possible to use active vaccination to harness the immune 
system and reinstate immune surveillance by overcoming 
tumor-associated immune suppression. 
Currently, vaccine-based cancer immunotherapy 
remains largely hindered by the lack of potent tumor 
antigens and by the tumor-induced immune suppressive 
cells such as MDSCs [10]. For example, despite its 
immunogenic potential of wilms’ tumor protein 1 (WT1) 
in mice and clinical trials [11], our data indicated that 
a WT1-based vaccine was not able to induce potent 
CD8+ T cells to either prevent or cure WT1-expressing 
mesothelioma [5]. Thus, it becomes critical to investigate 
if there are any other mesothelioma antigens for eliciting 
efficacious CD8+ T cells. As for tumor-induced immune 
suppression, MDSCs originated from the bone marrow 
are largely accumulated in tumor microenvironments 
[12]. MDSCs are a phenotypically heterogeneous 
population consisting of monocytic MDSCs (M-MDSCs) 
and polymorphonuclear MDSCs (PMN-MDSCs), of 
which both can dampen the immune response through the 
inhibition of T cell activation and proliferation [9, 13]. 
Efficacious CD8+ T cells, therefore, should overcome the 
immune suppressive effects of tumor-induced MDSCs [5, 
14]. 
Based on these observations and publications by 
others [15, 16], we hypothesized that antigen spreading 
after vaccine-induced CTL killing of AB1-GAG 
mesothelioma cells should be immunogenic for triggering 
tumor-specific immune responses against wild-type AB1 
mesothelioma, namely WT-AB1.. We show here that 
antigen-spreading during the repeated eliminations of 
AB1-GAG mesothelioma by sPD1-p24fc/EP vaccinations 
indeed resulted in the generation of effective tumor-
specific cytotoxic CD8+ T cells, which were capable of 
inhibiting PD1/Tim3 expression on their surface, reducing 
the number of MDSCs, and rejecting WT-AB1 malignant 
mesothelioma. 
rEsULts
sPD1-p24fc/EP DNA vaccination protects mice 
completely against three consecutive lethal 
challenges of Ab1-GAG malignant mesothelioma
In a previous study, we demonstrated that high 
frequency of CD8+ T cells elicited from sPD1-p24fc/
EP vaccination achieved complete and long-lasting 
protection of BALB/c mice from two lethal AB1-GAG 
challenges that expresses the same p24 antigen [5]. In 
order to develop a model for the induction of anti-tumor 
immune responses following in situ tumor destruction, we 
sought to increase the frequency of AB1-GAG challenge 
up to three times while shortening the time span of each 
implantation. By the same immunization protocol [6, 17], 
we vaccinated groups of BALB/c mice intramuscularly 
(i.m.) via immediate electroporation (EP) over the 
injection site three times at three-week intervals with 100 
μg plasmid DNA of sPD1-p24fc, p24fc or PBS control in a 
volume of 100 μl. Two weeks after the last immunization, 
three consecutive rounds of subcutaneous (s.c.) AB1-
GAG inoculations were performed at two-week intervals 
on their left flank (Figure 1A). We consistently found 
that all sPD1-p24fc/EP vaccinated mice cleared implanted 
AB1-GAG cells within two weeks and survived after 
the consecutive tumor challenges (Figure 1B and 1C). 
In contrast, none of the animals in control groups could 
withstand one time tumor challenge and died within 4-6 
weeks. Bioluminescence imaging (BLI) was taken every 
week after tumor implantation. Comparison was made 
based on the intensity of luciferase signal from the region 
of interest (ROI), showing that vaccination with sPD1-
p24fc/EP led to a significant suppression of AB1-GAG 
tumor progression (Figure 1B and 1C, **P = 0.007). 
These results suggested that sPD1-p24fc/EP vaccination 
effectively eliminated three times of AB1-GAG malignant 
mesothelioma challenges, resulting in the establishment of 
a vaccine-mediated tumor destruction model. This model 
provided a useful system to address the critical question 
of whether three times of AB1-GAG elimination would 
induce antigen spreading and lead to the induction of 
tumor-specific immunity against WT-AB1.
Mice protected from Ab1-GAG challenges 
generate antibody and cD8+ t cell responses 
against Wt-Ab1 malignant mesothelioma
Our previous data indicated that the presence of 
cytotoxic CD8+ T cells is an important factor responsible 
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for the eradication of AB1-GAG by releasing inflammatory 
IFN-γ and TNF-α in the vicinity of target cells as well as 
by initiating TRAIL-directed tumor cell apoptosis [5]. 
Cell debris released after tumor destruction then becomes 
a potential antigen repertoire for reinitiating immune 
responses suppressed by the tumor microenvironment 
[18]. However, little is known regarding the functional 
characteristics of anti-tumor immune responses induced 
by the mesothelioma destruction. For this reason, we 
sought to determine antibody and T cell responses against 
WT-AB1 mesothelioma. Indeed, after three times of AB1-
GAG elimination, we detected specific IgG antibodies that 
could react to WT-AB1 cells by flow cytometric analysis. 
As shown in Figure 2A, all protected mice have developed 
WT-AB1-specific antibody responses. The binding of anti-
sera to WT-AB1 cells resulted in an increased fluorescent 
signal shifted dose-dependently to the right as compared to 
control sera (Figure 2A, left panel). Antibody-dependent 
cell mediated cytotoxicity (ADCC) may play a role in 
elimination of tumor cells through activating effector 
neutral killer (NK) cells [19]. Using the same method, 
we then measured the ADCC activities of these anti-sera 
derived from sPD1-p24fc/EP/AB1-GAG (group I), sPD1-
p24fc/EP/PBS (group II) or placebo control mice (group III) 
at different dilutions (1:5, 1:10, 1:20 and 1:100). However, 
murine sera from three groups showed no significant 
difference (data not shown), thus, these reactive anti-
sera, may not mediate ADCC effects against WT-AB1. 
Subsequently, we sought to measure T cell responses 
against WT-AB1. Both CD4+ and CD8+ T cells purified 
from splenocytes of immunized-protected mice were 
subjected to cytotoxicity assays, respectively. Luciferase-
expressing WT-AB1 tumor cells (2 x 104/well) were 
seeded as target cells in this experiment. Purified CD8+ or 
CD4+ T cells were assayed at different effector:target (E/T) 
ratio from 0.5:1 to 20:1. Clearly, CD8+ T cells isolated 
from group I mice showed a strong cytotoxic effect against 
WT-AB1 cells in vitro at E/T ratios of 10:1 and 20:1 
(Figure 2B, ***P = 0.00078). In contrast, CD4+ T cells 
did not show significant cytotoxic activities (Figure 2C). 
Although both antibody and CD8+ T cell responses were 
elicited during the process of AB1-GAG elimination, only 
Figure 1: complete protection of mice against three consecutive lethal challenges of Ab1-GAG mesothelioma. A. 
Schematic representation of a prophylactic study on the sPD1-p24fc/EP DNA vaccine against repeated AB1-GAG mesothelioma challenges. 
b. After three consecutive lethal challenges of 5x105 AB1-GAG mesothelioma cells, tumor growth was assessed by BLI as compared with 
p24fc/EP-vaccinated mice. **P = 0.007. Data was plotted as mean ± s.e.m. c. Representative BLI of AB1-GAG tumor growth in vaccinated 
mice according to the experimental time schedule A.. Images were acquired at the indicated time points after tumor cell inoculation. The 
color scale indicates the BLI signal intensity. Two independent experiments generated the same results.
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CD8+ T cells exhibited capacity in killing WT-AB1 cells. 
Therefore, under our experimental conditions cell debris 
released after AB1-GAG destruction likely induced tumor-
specific CD8+ T cell immune responses against WT-AB1. 
Mice protected from Ab1-GAG challenges show 
significant protection against WT-AB1 malignant 
mesothelioma
The induction of broad immune protection is highly 
Figure 2: Tumor-specific immune responses after three consecutive lethal challenges of AB1-GAG mesothelioma. A. 
Antibody binding to WT-AB1 cells by flow cytometry. Representative histogram shows the binding of 1:100 diluted anti-sera to WT-AB1 
cells with the fluorescent signal shifted to the right (unfilled peak) as compared to control sera (red filled peak). Pre-labeled anti-mouse IgG 
was used as the detection antibody (left panel). Using various serum dilutions, immune sera show consistent binding to WT-AB1 cells in 
a dose-dependent way as compared with the control sera (right panel). **P < 0.01; ***P < 0.001. b. In vitro CD8+ T cell cytotoxic assay. 
Representative bioluminescence images depict the luminescence intensity in each well at the E/T ratio of 20:1 (left panel). The degree 
of CTL-mediated killing of tumor cells was indicated by the decrease of luminescence activity using the IVIS100 luminescence imaging 
system (right panel). BLI signals were acquired for 20 second. **P = 0.0066; ***P = 0.00078. c. In vitro CD4+ T cell cytotoxic assay. 
Representative bioluminescence images depict the luminescence intensity in each well at the E/T ratio of 20:1 (left panel). There were no 
CD4+ T cytotoxic activities against tumor cells because of the lack of significant differences between experimental groups (right panel).
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desirable against tumors with unproven tumor antigens 
[20]. Cytolytic destruction of AB1-GAG tumor could 
lead to the modulation of antigen repertoire and spreading 
of tumor antigens that could induce tumor-specific T 
cell immunity responsible for tumor regression [21, 
22]. Accordingly, we sought to determine whether these 
protected mice would also show prophylactic effects 
against WT-AB1 challenge. The challenge was performed 
with a lethal dose of 5 x 105 WT-AB1 cells in the opposite 
right flank s.c. (Figure 3A). After the challenge, living 
images of tumor growth and animal survival were 
studied overtime (Figure 3B-3D). The sPD1-p24fc/EP/
AB1-GAG (group I) proved to be significantly more 
efficient than controls at rejecting implanted WT-AB1 
cells (Figure 3B, **P = 0.0098), and most protected mice 
(9/10, 90%) remained tumor-free. In contrast, all control 
mice developed tumors and died within 40 days (Figure 
3C, ***P = 0.0002). As described in our recent study, 
although sPD1-p24fc/EP vaccination was fully protective 
against AB1-GAG challenges (Figure 1), it did not provide 
any protective benefits against the lethal challenge of 
WT-AB1 [5]. By way of explanation, the immune state 
achieved by three times of sPD1-p24f/EP vaccination did 
not confer any protection against WT1-AB1, which is 
also demonstrated through the results of (group II in this 
study (Figure 3). The observed anti-WT-AB1 protective 
immunity, therefore, must require specific anti-tumor 
immunity generated during the process of AB1-GAG 
elimination mediated by p24-specific CD8+ T cells. 
cD8+ t cell response is responsible for the 
protection of the lethal challenge of Wt-Ab1 
malignant mesothelioma
We sought to further determine the correlation 
of immune protection against WT-AB1 in vivo. Using 
previously described experimental protocols [5], we 
conducted adoptive transfer of pooled anti-sera and 
purified CD8+ T cells derived from group I and control 
groups, respectively. Anti-sera from protected or 
unprotected BALB/c mice were transferred i.p. into 
immunodeficient SCID mice 3 days before the lethal 
challenge of WT-AB1, then another 3 boosts of the same 
Figure 3: Protection of mice against the lethal challenge of wild-type mesothelioma. A. Schematic representation of the study 
design. b. After a lethal dose of 5x105 WT-AB1 challenge, tumor growth was assessed by BLI overtime. Statistical analysis was done on 
day 21 between groups I and II or III (n = 5 in I and II, 3 in III). Data was plotted as mean ± s.e.m. **P = 0.0098; *P = 0.0376. c. Survival 
curve. The majority of mice (90%, 9/10) in group I survived after the WT-AB1 challenge and remained tumor free. Results were combined 
from two independent experiments with n = 5 each. ***P = 0.0002. D. Representative BLI depicts the growth of WT-AB1 mesothelioma in 
one of two independent experiments. Images were acquired at the indicated time points after the inoculation of WT-AB1.
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anti-sera were administered at day 1, 3, 5 after the tumor 
inoculation. In consistency with the lack of in vitro ADCC 
activities, results of BLI indicated that none of the infused 
anti-sera showed elimination of WT-AB1 tumor (data not 
shown). We then sought to determine the role of CD8+ 
T cells in tumor rejection in vivo by conducting T cell 
adoptive transfer experiments in the SCID mouse model. 
For this purpose, under a therapeutic setting, a lethal 
dose of 5 x 105 WT-AB1 cells were inoculated into SCID 
mice of groups I’, II’ and III’ 7 days before they received 
intravenous injection of purified CD8+ T cells from groups 
I, II and III, correspondingly (Figure 4A). As compared to 
groups II’ and III’, mice in group I’ receiving CD8+ T cells 
from protected mice showed significant elimination of 
WT-AB1 tumor (Figure 4B and 4C, *P = 0.0194). Again, 
HIV-1 p24-specific CD8+ T cells induced by three times of 
sPD1-p24fc/EP vaccination did not confer any protection 
against WT-AB1 in group II’ (Figure 4), which is in 
agreement with previous findings (group II in Figure 3) [5]
Tumor-specific CD8+ t cells function by 
suppressing PD1/tim3 expression on their surface 
and by eliminating PMN-MDscs
To further illustrate the functionality of tumor-
specific CD8+ T cells in modulating tumor-associated 
immunosuppression, we isolated splenocytes from 
protected and control SCID mice, and analyzed the 
frequency of MDSCs as well as the expression of 
exhaustion markers PD1 and Tim3 on CD8+ T cells. 
Tumor-free mice in group I’ consistently retained 
the low expression of PD1 (**P = 0.0058) and Tim3 
(**P = 0.0028) on CD8+ T cells (Figure 5A) as well 
as significantly reduced frequencies of MDSC (*P = 
0.0303). Interestingly, one unprotected mouse from group 
I’ displayed a high frequency of MDSCs. Correlation 
analysis indicated that the frequency of non-exhausted 
PD1-Tim3- CD8+ T cells was inversely correlated with that 
of MDSC significantly (Figure 5B, left, ***P =  0.0001) 
as well as with tumor mass (Figure 5B, right, ***P < 
0.0001). 
To investigate MDSC in a different experimental 
condition, we studied immuncompetent BALB/c mice. 
We previously demonstrated that the frequency of 
MDSCs can increase significantly in BALB/c mice, 
accounting for approximately 10% of total splenocytes 
after the transplantation of syngeneic AB1 mesothelioma 
[5]. Here, we found that the splenic MDSC population 
of AB1-bearing mice was consisted of two distinct 
subpopulations characterized by CD11b+Ly6G+Ly6Clow/
int polymorphonuclear (PMN) MDSCs and CD11b+Ly6G-
Ly6Chi monocytic (M) MDSCs (Figure 6A). Moreover, 
PMN-MDSCs dominated over 80% of the total MDSCs in 
Figure 4: Adoptive transfer of tumor-specific CD8+ t cells eliminates established Wt-Ab1 malignant mesothelioma. 
A. Time schedule of the adoptive transfer of CD8+ T cells. SCID mice were pre-inoculated s.c. with 5x105 WT-AB1 cells, and tumors were 
left to grow for 7 days to reach approximately 5 mm in length. Cyclophosphamide (Cy) was injected intraperitoneally (150 mg/kg) one 
day before the adoptive transfer of CD8+ T cells. 2x106 of isolated CD8+ T cells in 100 μl PBS were then injected via the tail vein into each 
mouse. b. Tumor growth was assessed by BLI overtime. CD8+ T cells of groups I, II and III were adoptively transferred i.v. into SCID mice 
of groups I’, II’ and III’, correspondingly. Intravenous transfer of CD8+ T cells of group I significantly eliminated established WT-AB1 
tumor in SCID mice of group I’ (n = 5). Data represent mean ± s.e.m. *P = 0.0194. c. Representative BLI of WT-AB1 tumor growth in 
three groups of SCID mice. Images were acquired at the indicated time points after WT-AB1 tumor inoculation. 
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AB1-bearing mice. By measuring the expression of active 
caspase-3 and annexin V, we found that M-MDSCs were 
prone to apoptosis and had a significantly shorter life-span 
than PMN-MDSCs in vitro (Figure 6B). The higher levels 
of Fas and DR5 expression might render M-MDSCs more 
susceptible to apoptosis within 16 h in vitro (Figure 6A-
6B) [23, 24]. 
We then sought to measure the interaction 
between CD8+ T cells and the dominant PMN-MDSCs. 
Protective CD8+ T cells and PMN-MDSCs purified from 
protected group I mice (Figure 3) and AB1-bearing mice, 
respectively, were co-cultured for analysis of active 
caspase-3 and annexin V expression on PMN-MDSCs 
by flow cytometry as described above (Figure 6B). As 
compared with control CD8+ T cells, protective CD8+ 
T cells not only exhibited relatively higher levels of 
TRAIL and FasL expression in two separate experiments 
(Figure 6C) but also released higher levels of IL-2 and 
IFN-γ (Figure 6D), and resulted in significant apoptosis 
of co-cultured PMN-MDSCs in a dose-dependent 
manner (Figure 6E). Interestingly, less IL-2 and IFN-γ 
were produced at MDSC:CD8 ratio of 1:1 as compared 
with CD8+ T cells alone (Figure 6D), indicating a 
likely suppressive effect of co-cultured CD8+ T cells 
by MDSCs. Conversely, when increased CD8+ T cells 
were presented at MDSC:CD8 ratios of 1:2 or 1:5 in the 
culture, significantly more IL-2 and IFN-γ were produced 
as compared with CD8+ T cells alone (Figure 6D). 
These data provide evidence that although MDSC may 
contribute to the suppression of CD8+ T cell function and 
support the progression of tumors [9], high frequency of 
functional tumor-specific PD1-Tim3- CD8+T cells might 
eliminate PMN-MDSCs through apoptosis to counteract 
the suppressive effect of MDSCs while lead to impeded 
tumor growth [23, 24]. 
DIscUssION
A critical challenge in mesothelioma 
immunotherapy is to reveal the mechanism of efficacious 
vaccine responses. Here, we demonstrate that CD8+ T cells 
induced by the vaccine-mediated antigen spreading are 
tumor-specific and confer significant protection against the 
lethal challenge of wild-type mesothelioma. Besides the 
inverse correlation between the frequency of efficacious 
PD1-Tim3- CD8+ T cells and that of MDSCs or tumor mass 
in vivo, these functional CD8+ T cells not only kill wild-
type mesothelioma in vivo but also lead to apoptosis of 
the predominant PMN-MDSCs significantly in a dose-
dependent manner. Our findings, therefore, may have 
implications to cancer immunotherapy. 
Cancer immunotherapy has been hindered by poor 
Figure 5: Frequency and correlation analysis of cD8+ t cells and MDsc in spleens of scID mice of groups I’, II’ and 
III’. A. Frequencies of MDSC, PD1+ CD8+ T cells, and Tim3+ CD8+ T cells were measured at the experimental endpoint (Figure 4A). Data 
represent mean ± s.e.m. *P < 0.05; ** P < 0.01; ***P < 0.001. b. The frequency of PD1-Tim3- CD8+ T cells was inversely correlated with 
that of MDSC (left panel) and with tumor mass (right panel), respectively. 
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Figure 6: In vitro analysis of MDscs and cD8+ t cells. A. Flow cytometry analysis of MDSC subpopulations isolated from spleens 
of WT-AB1-bearing mice (left panel). Different levels of Fas and DR5 expression were found between PMN-MDSCs and M-MDSCs (right 
panel). b. The expression of active caspase-3 and annexin V overtime. The majority of M-MDSCs undergo apoptotic cell death faster than 
PMN-MDSCs during the in vitro culture. c. Flow cytometry analysis of FasL (left panel) and TRAIL (right panel) expression on CD8+ 
T cells isolated from spleens of group I and control mice. D. IL-2 and IFN-γ production from co-cultures of WT-AB1-induced MDSCs 
with group I CD8+ T cells but not with control CD8+ T cells at different MDSC:CD8+ ratios of 1:1, 1:2 and 1:5. Data represent mean ± 
s.e.m. Results are representative of three independent experiments. E. By measuring the expression of caspase-3 and annexin V, significant 
proportions of apoptotic PMN-MDSCs were detected in co-cultures with group I CD8+ T cells as compared with control CD8+ T cells at 24 
h. Data represent mean ± s.e.m. Results are representative of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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CD8+ T cell responses against tumor-specific antigens 
because tumor cells often evolve to escape immune 
recognition and develop resistance through mutation or 
other mechanisms [25-27]. To avoid immune escape, one 
immunotherapy strategy is to target a broad repertoire 
of tumor antigens through vaccination of tumor cDNA 
library or combinatorial DNA vaccines [28, 29]. For the 
same purpose, another strategy is to provoke antigen 
spreading, a process that CD8+ T cell responses initiated 
by a vaccine trigger immune-mediated lysis of tumor cells, 
leading to the secondary immunity targeting at distinct and 
broader tumor antigens [30, 31]. The benefits of antigen 
spreading have been documented for vaccine-based 
immunotherapy against malignant melanoma and breast 
cancer [22, 32, 33]. Before the present study, however, it 
remained unknown if vaccine-mediated antigen spreading 
could be used for treating malignant mesothelioma. By 
a model vaccine-mediated antigen spreading, we show 
here that broad host immunity, including both humoral 
and cellular responses are elicited against wild-type 
mesothelioma. Moreover, we demonstrate that tumor-
specific cytotoxic CD8+ T cells, but neither CD4+ T cells 
nor antibodies, confer the protection, suggesting that 
CD8+ T cells may play a central role in antigen spreading-
mediated immunotherapeutic efficacy against malignant 
mesothelioma in mice. 
In our previous study, using HIV-1 GAG-p24 in 
the model sPD1-p24fc/EP vaccine, we show that vaccine-
elicited CD8+ T cells confer complete prevention and 
therapeutic cure of AB1-GAG malignant mesothelioma 
in immunocompetent BALB/c mice [5]. These efficacious 
CD8+ T cells display antigen-specific property and 
require a high frequency for function. Here, we show 
that the vaccine-mediated elimination of AB1-GAG 
mesothelioma results in the induction of tumor-specific 
CD8+ T cells through antigen spreading, which protect 
mice from the subsequent wild-type mesothelioma. sPD1-
p24fc/EP vaccination achieved a functional state during 
the course of AB1-GAG regression (Figure 1-2) that 
not only prevents the rise of exhausted PD1+ and Tim3+ 
CD8+ T cells but also reduces tumor-induced MDSCs 
(Figure 5) [5]. It is possible that such a microenvironment 
is critical for the induction of high quality of tumor-
specific effector PD1-Tim3- CD8+T cells (Figure 5), 
which are capable of dramatically reducing the presence 
of MDSCs and improving immunotherapeutic responses 
in tumor-bearing mice [3]. However, it is still unknown 
which tumor antigens are responsible for eliciting the 
efficacious CD8+ T cells and therefore we are not able to 
measure their frequency and functionality. Nevertheless, 
our newly established experimental platform is useful for 
future identification of mesothelioma antigens responsible 
for the induction of protective effector CD8+ T cells. 
Since antigen-specific CD8+ T cells are enriched within 
mesothelioma [5], future investigation may unravel the 
protective tumor epitopes by focusing on these cells [34]. 
To this end, the detailed analysis of high avidity CD8+ 
T cell receptor in recognition of novel mesothelioma 
epitopes is warranted [35, 36]. Subsequently, these 
epitopes can be potentially tested in the context of PD1-
based vaccine to amplify tumor-specific CD8+ T cells for 
therapeutic cure of mesothelioma [5]. 
Tumor-associated immunosuppressive network is a 
significant obstacle to an effective cancer immunotherapy 
[9]. Accordingly, regulatory T lymphocytes (Treg), tumor-
associated MDSCs, tumor-associated macrophages, and 
dysfunctional dendritic cells may contribute to such a 
complex immunosuppressive network. Among them, 
MDSCs have emerged as one of the central regulators 
because they can inhibit T cell function potently and 
modulate the development of Treg cells [10, 12]. However, 
previous studies have shown that high frequency of 
broadly reactive anti-tumor T cell responses may lead 
to the reduction of MDSCs [5, 14]. Such reduction 
was thought of as a result of efficient elimination of 
tumor cells by efficacious CD8+ T cells, and therefore 
less MDSCs are induced by the regressing tumor. Few 
studies have demonstrated the elimination of tumor-
induced MDSCs by efficacious CD8+ T cells. Here, we 
show that mesothelioma induces predominantly PMN-
MDSCs in vivo. Moreover, PMN-MDSCs express death 
receptors Fas and DR5 (Figure 6A), making them prone 
to apoptosis by efficacious CD8+ T cells, which exhibit 
higher FasL and TRAIL expression and predominant IL-2/
IFN-γ production (Figure 6C-6D) [23, 24]. Besides the 
significant inverse correlation between the frequency of 
functional PD1-Tim3- CD8+T cells and that of MDSCs or 
tumor mass in vivo (Figure 5A-5B), in co-cultures with 
efficacious CD8+ T cells, a significant number of PMN-
MDSCs underwent apoptosis in a dose-dependent way 
(Figure 6E). Thus, through initiation of MDSCs apoptosis 
to counteract their suppressive effect, higher frequency 
of efficacious CD8+ T cells could maintain their effector 
function (Figure 6C) [37]. This new finding indicates 
that vaccine-induced CD8+ T cells capable of eliminating 
both tumor cells and MDSCs are likely necessary for 
an effective immunotherapy against the malignant 
mesothelioma [23, 24]. 
MAtErIALs AND MEtHODs
Animal and cell lines
All animal experiments were approved by the 
Committee on the Use of Live Animals in Teaching and 
Research (CULATR) of The University of Hong Kong 
(HKU, #2438-11). 5- to 8-week- old female BALB/c and 
C.B-17/Icr-scid (SCID) mice were maintained according 
to standard operational procedures at HKU Laboratory 
Animal Unit (LAU). AB1 cells were purchased from 
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European Collection of Cell Cultures and transduced 
with a lentiviral vector to express luciferase in WT-AB1 
or luciferase together with HIV-1 GAG in AB1-GAG 
as previously described [5]. Transduced WT-AB1 and 
AB1-GAG were maintained in RPMI-1640 medium 
supplemented with 10% FBS and 1μg/ml puromycin 
(Invitrogen).
Mouse immunization and tumor challenge
Groups of BALB/c mice were intramuscularly (i.m.) 
immunized with 100 μg of plasmid DNA of sPD1-p24fc, 
p24fc or PBS control in a total volume of 100 μl, followed 
immediately by electroporation (EP) over the injection 
site using the TERESA gene delivery device (Shanghai 
Teresa Bio-Tech Co., Ltd.) as previously described [6]. 
The DNA/EP vaccination was repeated twice at three-
week intervals. For tumor challenge, 5 x 105 AB1-GAG 
cells were inoculated in the left flank subcutaneously 
(s.c.). Tumor implantation was repeated two more times 
at two-week intervals. The final tumor challenge was 
performed s.c. with a lethal dose of 5 x 105 WT-AB1 cells 
in the right flank. In vivo bioluminescence imaging (BLI) 
was taken once a week during the experiment and the 
luciferase intensity was measured in the region of interest 
(ROI) using the IVIS100 Imaging System (Caliper Life 
Science). Tumor size was also measured using calipers. 
Based on the CULATR guidelines, mice were sacrificed 
when tumors reached a size greater than 15 mm. 
splenocyte collection and t cells isolation
To wash the cells out of the spleen capsule, a 
tuberculin syringe containing PBS was used to inject the 
spleen in several places. Splenocytes were collected for 
T cell isolation using the mouse splenocyte separation 
medium (Dakewei biotech) via the discontinuous gradient 
centrifugation. CD4+ or CD8+ T cells were then purified 
using Dynabeads Untouched T Cell Kits according to the 
manufacturer’s instruction (Invitrogen). 
In vitro t cell cytotoxicity assay
Luciferase-expressing WT-AB1 cells (2 x 104/well) 
were cultured in 96-well plate one day before the addition 
of purified CD8+/CD4+ T cells at E/T ratios from 0.5:1 
to 20:1. Bioluminescence imaging (BLI) was taken 6 
hours after incubation. The level of luminescence activity 
reflects the degree of CTL-mediated killing of tumor cells 
under the IVIS100 Imaging System (Caliper Life Science) 
as previously described [38].
Antibody-dependent cell mediated cytotoxicity 
(ADcc) assay
The LIVE/DEAD Viability/ Cytotoxicity Kit 
(Invitrogen) was used in this assay. Briefly, WT-AB1 
cells (2x104/well) were resuspended in 1:250 diluted 
3, 3’-dioctadecyloxacarbocyanine (DiO) solution and 
incubated for 20 min in the 37°C tissue culture incubator. 
WT-AB1 cells were then washed and resuspended in 
1:100 or 1:1000 diluted anti-sera, respectively. Effector 
splenocytes (1 x 107/ml and 100 μl) were transferred into 
each tube to mix with target WT1-AB1 cells at an effector-
to-target (E/T) ratio of 50:1. Mixed cells were incubated 
for 4 hours in the 37°C incubator. After that, cells were 
collected and transferred into fresh culture medium 
containing 1:500 diluted propidium iodide (PI) and 
incubated for 10 min before analysis on a FACSCalibur 
instrument (BD Bioscience) and Flowjo software (Tree 
Star, version 7.6). 
Adoptive transfer of t cells
SCID mice were inoculated s.c. with 5x105 WT-
AB1 cells on their left flank. Tumors were left to grow 
for 7 days until they were visible (approximately 5 
mm in length). Cyclophosphamide (Cy) was injected 
intraperitoneally (150 mg/kg) one day before the adoptive 
transfer to promote the activation and proliferation of 
transferred cells without affecting tumor growth [39]. On 
the following day, 2x106 of isolated CD8+ T cells in 100 μl 
PBS were injected via tail vein into each mouse. 
MDsc isolation and culture
MDSCs from AB1-bearing BALB/c mice 
were isolated from their spleens using the Myeloid-
Derived Suppressor Cell Isolation Kit according to 
the manufacturer’s protocols (Miltenyi Biotech). The 
purity of PMN-MDSCs (CD11b+Ly6G+Ly6Clow/int) and 
M-MDSCs (CD11b+Ly6G-Ly6Chi) was greater than 95% 
as determined by flow cytometry. To assess CD8+ T cells 
mediated apoptosis, MDSCs and freshly isolated CD8+ 
T cells were co-cultured at MDSC-to-CD8+ T-cell ratios 
of 1:1, 1:2, and 1:5 in the 37°C tissue culture incubator 
for 24 hours before they were subjected to analysis of 
active caspase-3 and annexin V expression. Cell-free 
supernatants were also collected from the co-culture for 
cytokine quantification using the mouse Th1/Th2/Th17 
10-plex FlowCytomix Kit according to the manufacturer’s 
instruction (eBioscience).
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Flow cytometry
Monoclonal antibodies (mAbs) specific for mouse 
cell surface markers CD3, CD4, CD8, CD11b, Gr-1, 
Ly6G, Ly6C, Fas and DR5 were all purchased from 
eBiosciences. The intracellular staining of cleaved 
caspase-3 was performed using BD Cytofix/Cytoperm kit. 
The mAbs specific for the cleaved caspase-3 and Annexin 
V were obtained from BD Bioscience. The staining 
protocols were followed according to the manufacturer’s 
recommendations (BD Biosciences). 
statistical analysis
A two-tailed Student t-test was performed to 
determine statistical significance between different groups. 
P value less than 0.05 was considered to be statistically 
significant. Survival of mice was plotted to a Kaplan-Meier 
survival curve and the observed difference was determined 
by the log-rank test (GraphPad Prism 5 software). Data 
are presented as the mean values ± standard error (s.e.m.). 
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